MO01.44 Prognostic Factors in Extensive-Stage Small Cell Lung Cancer (SCLC)

Abstract

SCLC accounts for 13% of lung cancer cases and is characterized by a rapid growth and early metastatic spread, with about 65% of patients (pts) diagnosed in extensive stage. Standard first-line chemotherapy (ChT) hasn’t change over the last 4 decades. Despite high tumor response rates, most patients relapse within 6 months. Performance status (PS), gender, age, and body weight loss has traditionally been used to predict outcomes of pts with SCLC. The purpose of this analysis is to evaluate real world data of SCLC pts regarding survival outcomes and prognostic factors.